Amid Trump admin's drug pricing push, FDA aims to give biosimilars a boost
29th October 2025 Uncategorised 0The FDA has revealed a set of measures designed to increase the availability of biosimilars in the United States and in turn reduce the price of biologic medicines after they lose patent protection. In new draft guidance, the FDA has taken steps to eliminate the clinical testing of biosimilars and to categorize all approved biosimilars as “interchangeable.”
More: Amid Trump admin's drug pricing push, FDA aims to give biosimilars a boost
Source: fierce